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Abstract
Background: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS of still unknown
aetiology. Flammer syndrome (FS) encompasses a set of symptoms and signs that are primarily but not solely
related to the dysregulation of blood vessels. The purpose of the present study was to determine whether FS
symptoms occur more often in MS patients than in controls.
Methods: Fifty-eight MS patients and 259 controls answered a questionnaire covering 15 symptoms and signs
of FS.
Results: Six of the 15 symptoms and signs of FS (dizziness, low body mass index, cold hands and/or feet,
tendency toward perfectionism, reduced thirst, feeling cold) were found significantly more often in MS
patients than in controls. Seven additional symptoms and signs (tinnitus, headaches, increased pain sensation,
long sleep-onset time, migraines, increased response to certain drugs, low blood pressure) also occurred more
often in MS patients, but the difference in frequency was not statistically significant. One sign (reversible skin
blotches) was found less often in MS patients, but the difference in frequency was not statistically significant.
One symptom (increased smell perception) was found significantly less often in MS patients.
Conclusions: MS patients suffer significantly more often from FS symptoms and signs than controls. The
reason for this association between MS and FS and the potential implications of this association still need to
be determined.
Keywords: Multiple sclerosis (MS), Flammer syndrome (FS), Primary vascular dysregulation (PVD),
Questionnaire, Predictive diagnostics, Targeted prevention, Personalized medicine
Background
Multiple sclerosis (MS) is a chronic, demyelinating, degen-
erative disease of the central nervous system. It is the most
common neurologic disorder of young adults, with ap-
proximately 2.5 million individuals affected worldwide. The
lesions are typically disseminated and lead to a wide variety
of symptoms. The clinical course is usually fluctuating and
can lead to severe and irreversible disability [1, 2]. The dis-
ease was first described more than 150 years ago [3].
Whilst we know that MS is an immune-mediated inflam-
matory and neurodegenerative disease, there is still contro-
versy about its cause [4–7].
Since the first description of the disease by Charcot,
vascular changes have also been repeatedly described as
occurring more often in MS patients [8], particularly in
the eye [9–11]. The inflammation also involves vascular
and perivascular tissue and thereby influences brain per-
fusion. But systemic vascular changes have also been de-
scribed. Most of these studies focused on atherosclerosis
and its risk factors [12]. To the best of our knowledge,
the prevalence of primary vascular dysregulation (PVD)
[13, 14] (the vascular component of Flammer syndrome
(FS) [15]), already described in eye diseases such as glau-
coma [16, 17] and retinitis pigmentosa [18, 19], has not
yet been studied in MS. The FS describes the phenotype
of subjects with an inherited increased sensitivity and al-
tered response pattern (particularly of the blood vessels)
to a number of stimuli like coldness or emotional stress.
The purpose of this study was to investigate the fre-
quency of FS-related symptoms and signs in MS patients
compared to controls with the help of a multiple-choice
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questionnaire. Knowing that the frequency of the symp-
toms of interest may vary between nations [20], we com-
pared Swiss MS patients with Swiss controls.
Methods
Participants
Fifty-eight MS patients at the Department of Neurology
and Neurorehabilitation, Rehabilitation Centre Valens in
Valens, Switzerland (34 women and 24 men; 16 relapsing-
remitting, 28 secondary progressive and 14 primary pro-
gressive forms, diagnosed according to revised McDonald
criteria, EDSS (Expanded Disability Status Scale) 2.5–8.5,
average 5.58), anonymously filled out our questionnaire.
The patients’ age ranged from 36 to 76 years (mean 44.7
± 14.2). At the same time, 259 control subjects (150
women and 109 men) visiting shopping centres were re-
cruited and asked to anonymously fill out the same ques-
tionnaire. The control subjects’ age ranged from 18 to
89 years (mean 51.4 ± 18.0). Both MS patients and healthy
subjects received a questionnaire with the information
that they can voluntarily and anonymously fill it out. We
did not use inclusion or exclusion criteria in either group:
the only difference between these groups was the presence
or absence of MS. This study was not submitted to an eth-
ics committee for approval before the work began, and the
ethics committee cannot approve the study retrospect-
ively. However, the Kanton St. Gallen Ethikkommission
have indicated that if the project would have been submit-
ted to the ethics committee prior to initiation, there would
have been a high likelihood for ethics committee approval
and that this should not preclude publication. All subjects
completed the study without any complaints.
Questionnaire
The questionnaire (Flammer Syndrome Questionnaire)
consisted of 15 multiple-choice items with the following
choices: ‘often’, ‘sometimes’, ‘never’ or ‘I do not know’.
The questionnaire items are listed in Table 1.
Statistical analysis
In order to study the effect of the questionnaire items
on MS patients compared to control subjects, a logistic
regression analysis was performed, with each item used
as a predictor. The most positive answer category was
compared to the combined remaining answer categories
(e.g. ‘sometimes’, ‘never’ and ‘I do not know’). Results are
reported as odds ratios (ORs) and 95 % confidence inter-
vals (CIs), with corresponding p values. Additionally,
age, gender and a possible interaction between gender
and each item were included in the regression models. A
p value of <0.05 was considered significant. This study
was exploratory; therefore, p values were not adjusted
for multiple comparisons. All analyses were completed
using R version 2.12.0 [21].
Results
Each questionnaire item was compared between MS pa-
tients and controls. The results are reported as odds ra-
tios and sorted according to the degree of difference
between the two groups, beginning with the largest de-
gree of difference (Fig. 1). Ratios greater than 1.0 indi-
cate a higher frequency of the symptom or sign in MS
patients, and ratios less than 1.0 indicate a higher fre-
quency of the symptom or sign in controls.
Six of the 15 symptoms and signs of FS were present
significantly more often in MS patients than in controls.
These were dizziness, low body mass index, cold hands
and/or feet, tendency toward perfectionism, reduced
feeling of thirst and feeling cold. Seven additional symp-
toms and signs also tended (although not statistically
significantly) to occur more often in MS patients. These
were tinnitus, headaches, increased pain sensation, long
sleep-onset time, migraines, increased response to cer-
tain drugs and low blood pressure. One sign (reversible
skin blotches) tended (although not statistically signifi-
cantly) to occur less often in MS patients. One symptom
(increased smell perception) was present significantly
less often in MS patients.
ORs were adjusted for gender and age. No interactions
between gender and any of the items were significant;
therefore, interactions were not included in the regres-
sion models.
Discussion
The present study reveals that 13 out of the 15 symp-
toms and signs characteristic of FS occur more often in
MS patients than in controls. The difference in fre-
quency was found to be statistically significant for six
Table 1 Symptoms and signs of Flammer syndrome
Cold hands or/and feet
Reduced feeling of thirst
Low blood pressure
Dizziness









Reversible skin blotches (red or white)
Tendency toward perfectionism
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symptoms and signs and statistically insignificant for
seven symptoms and signs. MS patients, however, indi-
cated significantly reduced smell perception.
The findings of our study partly confirm previous re-
ports, but they also reveal new information. Our MS pa-
tients suffer more often from dizziness than controls.
Indeed, dizziness in MS has already been reported in the
literature [22]. In addition, about 60 % of the MS pa-
tients have been reported to suffer from disequilibrium
[23]. We found that our MS patients indicated more
often to be slim than the controls. This is in agreement
with previous studies. Compared to the general popula-
tion, MS patients have lower rates of excess weight and
obesity, as assessed by BMI. However, the literature is
not homogenous. Some recent studies have shown that
obesity (in particular adolescent obesity) might be a risk
factor for MS [24, 25]. It is well possible that both
extremes—very low and very high BMI—could increase
the risk. Our findings show that MS patients subject-
ively suffer more often from cold extremities and more
often feel cold than controls. This is also in agreement with
previous reports. Thermoregulation dysfunction has already
been described [26], but to the best of our knowledge, cold
extremities in MS have not yet explicitly been reported in
the literature. Our patients more often show perfectionist
tendencies. Indeed, tendency toward perfectionism in MS
patients has already been described [27]. Our patients have
reduced feelings of thirst. This has not yet been described
and may be due to increased endothelin-1 levels in the
cerebrospinal fluid [28] or in the plasma [29]. Our results
show (although statistically insignificantly) that MS patients
more frequently suffer from tinnitus. Indeed, it has already
Fig. 1 Frequency of symptoms and signs of Flammer syndrome in patients with multiple sclerosis (MS) (n = 58) in comparison to unselected controls
(n = 259). For each of the questionnaire items listed in Table 1, results are presented as odds ratios (ORs) and 95 % confidence intervals (CIs), with
corresponding p values. Results are sorted according to the degrees of difference between the two groups, beginning with the largest degree of
difference. Ratios greater than 1.0 indicate that the symptom or sign occurs more often, and ratios less than 1.0 indicate that the symptom or sign
occurs less often in MS patients than in unselected controls
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been reported in the literature that 30 % of MS patients suf-
fer from tinnitus [23]; even sudden hearing loss has been
reported [30]. Our patients suffer more often (although sta-
tistically insignificantly) from headaches and migraines.
Several previous studies have shown that headaches occur
more frequently in MS patients than in controls or in the
general population. Headaches may occur at the pre-
symptomatic phase, at clinical onset and during the course
of the disease [31]. Status migrainosus [32] or cluster head-
aches can occur as the initial presentation of MS. MS pa-
tients have been reported to suffer often from migraines
[33]. Chronic pain is common among patients with MS.
This is also in agreement with the results of our study. Our
MS patients have a longer sleep-onset time. Sleep disturb-
ance is also a common symptom of MS [34, 35]. Although
increased odour perception is characteristic of FS, our MS
patients indicate decreased smell function. Smell function
is generally reduced in neurodegenerative diseases [36], and
this has also been described in the MS literature [37].
Taken together, our results reveal a relationship
between MS and FS. In addition to certain symptom-
related similarities, the two entities share additional as-
pects, such as female preponderance [13], early onset
and lower incidence in subjects with higher light expos-
ure [13, 35, 38, 39]. Many lines of evidence suggest that
higher serum vitamin D concentrations reduce the risk
for both manifestation and progression of MS. MS and
FS share further aspects, such as increased rigidity of
the retinal vessels [40, 41], increased endothelin-1
plasma level [29, 42] and increased frequency of retinal
gliosis-like alterations [13, 43, 44]. MS also shares some
similarities with Susac’s syndrome, a vascular disease
affecting the brain, retina and inner ear [45, 46]. Inter-
estingly, patients with Susac’s syndrome often suffer
from FS [47].
The phenomenology of FS has been described in detail
elsewhere [13–15]. Already described is a relationship
between FS and normal-tension glaucoma [16, 17], ret-
inal vein occlusion, retinitis pigmentosa [19] and Susac’s
syndrome, as recently summarized in a review [13]. To
the best of our knowledge, this is the first report of a po-
tential relationship between FS and MS.
The cause of this relationship remains at the moment
unknown, and the impact of vascular dysregulation on
the pathogenesis of MS remains open. There are several
possibilities: MS could induce these symptoms (in terms
of a secondary vascular dysregulation [13]), or subjects
with FS may have a higher risk of developing MS. One
could hypothesize that FS leads to clinically undetected
microinfarctions in the central nervous system, trigger-
ing an autoimmune disease. FS also leads to increased
oxidative stress [16], which in turn could contribute to
the pathogenesis of MS [48–50]. A secondary vascu-
lopathy (particularly endotheliopathy), induced by the
autoimmune disease, could contribute to the chronic
progression of MS.
Limitations of the study We did not match for age and
gender; we did however include age and gender in the re-
gression model. We also did not ask study participants for
diseases except MS. MS is such a heterogenous disease that
any sample has a potential bias. In a rehabilitation centre,
patients with rather longer disease duration and higher
EDSS than in the ‘average MS population’ are treated. Po-
tentially confounding effects of immunomodulatory drugs
cannot be excluded as they cannot be determined in the
way this study was conducted. The study should be re-
peated with newly diagnosed MS patients without potential
confounding comorbidities and treatments.
Conclusions
MS patients suffer significantly more often from FS
symptoms and signs than controls. Future studies will
need to confirm the relationship between MS and FS
and, if it is found to be positive, to analyse the cause of
this relationship. FS is normally not treated in healthy
subjects. However, if it turns out to be a risk factor for
MS, prophylactic and preventive vascular treatment may
be helpful. Such an individualized treatment could be
based on the outcome of a vascular evaluation such as a
dynamic retinal vessel analysis [51].
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